Nektar Therapeutics logo

Nektar Therapeutics

1
NAS:NKTR (USA)   Ordinary Shares
$ 1.39 +0.04 (+2.96%) 10:08 PM EST
At Loss
P/B:
2.01
Market Cap:
$ 255.79M
Enterprise V:
$ 80.63M
Volume:
1.05M
Avg Vol (2M):
2.20M
Trade In:
Volume:
1.05M
At Loss
Avg Vol (2M):
2.20M

Business Description

Nektar Therapeutics logo
Nektar Therapeutics
NAICS : 325412 SIC : 2834
ISIN : US6402681083

Share Class Description:

NKTR: Ordinary Shares
Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Name Current Vs Industry Vs History
Cash-To-Debt 2.54
Equity-to-Asset 0.32
Debt-to-Equity 0.9
Debt-to-EBITDA -0.79
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -12.08
Distress
Grey
Safe
Beneish M-Score 15.38
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.65
9-Day RSI 56.69
14-Day RSI 54.74
6-1 Month Momentum % 113.16
12-1 Month Momentum % 101.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.1
Quick Ratio 5.79
Cash Ratio 5.52
Days Inventory 183.1
Days Sales Outstanding 9.19
Days Payable 58.43

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2
Shareholder Yield % -5.1

Financials (Next Earnings Date:2024-08-08 Est.)

NKTR's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NKTR

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Nektar Therapeutics Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 90.167
EPS (TTM) ($) -0.92
Beta 0.62
Volatility % 76.16
14-Day RSI 54.74
14-Day ATR ($) 0.127078
20-Day SMA ($) 1.27425
12-1 Month Momentum % 101.95
52-Week Range ($) 0.4126 - 1.928
Shares Outstanding (Mil) 184.02

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Nektar Therapeutics Filings

Filing Date Document Date Form
No Filing Data

Nektar Therapeutics Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Nektar Therapeutics Frequently Asked Questions

What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $1.39. The 52 week high of NKTR is $1.93 and 52 week low is $0.41.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2024-08-08 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1